ArticleEsophagus : official journal of the Japan Esophageal Society2022
In vitro anti-cancer effect of marmesin by suppression of PI3K/Akt pathway in esophagus cancer cells.
Article in Esophagus : official journal of the Japan Esophageal Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Safety and Tolerability of HemoHIM: A Randomized, Placebo-Controlled, Double-Blind, and Parallel Clinical Trial in Healthy Human Volunteers.Journal of microbiology and biotechnology · 2025Trial
- Jasmonic acid and nanoparticle elicitation ofRSC advances · 2026Article
- Solute carrier family 16 member 3 is a target of nodakenetin in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploring Natural Coumarins: Breakthroughs in Anticancer Therapeutics.Anti-cancer agents in medicinal chemistry · 2026Review
- Synthesis and anti-cancer biological evaluation of a novel protoapigenone analogue, WYC-241.RSC medicinal chemistry · 2025Article
- Medicinal Potential ofPlants (Basel, Switzerland) · 2025Review
- Jujuboside B Inhibits the Proliferation and Migration of Non-Small Cell Lung Cancer H1299 Cells Through Inhibiting PI3K/Akt and Wnt/β-Catenin Pathways.Cancer management and research · 2025Article
- The anti-inflammatory effects of oridonin in resisting esophageal cancer.Frontiers in oncology · 2025Article
- Article
- Insights into Tissue-Specific Specialized Metabolism in Wampee (Foods (Basel, Switzerland) · 2024Article
- Chemical Constituents from the Roots ofPharmaceutics · 2023Article
- The GenusMolecules (Basel, Switzerland) · 2022Review
- Potential Anticancer Activity of the Furanocoumarin Derivative Xanthotoxin Isolated fromMolecules (Basel, Switzerland) · 2022Article
- The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway.Journal of oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMarmesin, an important coumarin isolated from Broussonetia kazinoki, has been proposed to possess many pharmacological activities including anti-tumor activity. However, the anti-cancer effect of marmesin on esophageal cancer (EC) has not been characterized. The study aimed to explore the anti-cancer role of marmesin using EC cell lines in vitro. METHODS AND
resultsCell proliferation was evaluated by CCK-8 and Edu cell proliferation assays and apoptosis was detected by TUNEL assay. Western blot analysis was used to determine the expression of Ki67, proliferating cell nuclear antigen (PCNA), Bcl-2, Bax, phosphatidylinositol 3-kinase (PI3K), phosphoryrated-PI3K (p-PI3K), protein kinase B (Akt), and phosphoryrated-Akt (p-Akt). The mechanism of action of marmesin was analyzed using network pharmacology approach. Marmesin exhibited anti-proliferative effect against EC cells, which was further confirmed by the reduced expression of Ki67 and PCNA. Marmesin exerted pro-apoptotic activity on EC cells by downregulating Bcl-2 and upregulating Bax. According to the results from network pharmacology approach, we speculated that PI3K/Akt pathway may participate in the effect of marmesin on EC cells. Additionally, the PI3K/Akt pathway was suppressed by marmesin in EC cells. Moreover, forced expression of Akt reversed the inhibition of cell proliferation and induction of apoptosis induced by marmesin in EC cells.
conclusionsMarmesin exerted anti-cancer activity in EC cells by inhibiting the PI3K/Akt pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.